MS webcast: SNDX reiterated 3Q18—(next 9 days)—completion of enrollment and release of PFS data in the phase-3 trial in HR+/HER2- breast cancer. (The unusual trial protocol requires that enrollment be completed prior to the DSMB’s releasing the PFS analysis.)
The HR for PFS has to be ≤0.67 for success, according to the company (#msg-142755004). This doesn’t seem like an unattainably tough threshold, but the modest enterprise value of ~$60M implies that the market expects failure.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.